Business Potential for Agricultural Biotechnology - Asian Productivity ...
Business Potential for Agricultural Biotechnology - Asian Productivity ...
Business Potential for Agricultural Biotechnology - Asian Productivity ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
– 127 –<br />
Trends in Korean Animal <strong>Biotechnology</strong><br />
2003). The EPO protein has three N-glycosylation sites and one O-glycosylation site. N-glycosylation<br />
is considered the key player in the glycoprotein’s activity (Jelkmann, 1992). Not only<br />
the number but also the pattern of glycosylation seems important to the stability and activity of<br />
the protein. For example, instead of the normal three, Amgen’s new EPO product has five Nglycosylations<br />
to increase the half-life of the protein (Egrie and Browne, 2001).<br />
Table 1. World’s Top Biopharmaceutical Products (1996)<br />
Rank Product Company <strong>Business</strong> 1996 sales<br />
(USD<br />
1,000)<br />
1 Epogen Amgen Amgen 1,150<br />
2 Neupogen Amgen Amgen 1,017<br />
3 Procrit Amgen Ortho Biotech 995<br />
4 Humulin Genentech Eli Lilly 884<br />
5 Engerix-B Genentech SmithKline Beecham 568<br />
6 Intron A Biogen Schering-Plough 524<br />
7 Betaseron Chiron/Berlex Berlex/Schering AG 353<br />
8 Epivir BioChem Pharma/Glaxo Glaxo Wellcome<br />
Wellcome<br />
306<br />
9 Activase Genentech Genentech 284<br />
10 Humatrope Genentech/Eli Lilly Eli Lilly 268<br />
Total 6,348<br />
NLRI researchers have microinjected cloned transgene constructs into a one-celled embryo<br />
which was then transferred to a surrogate sow. The resulting piglets were identified by PCR<br />
using genomic DNA from each piglet’s tail. In 1998, a transgenic founder was identified out of<br />
47 candidate piglets using PCR and Southern blot analysis, both of which showed positive results<br />
<strong>for</strong> the founder individual. The founder was later named “Saerome,” meaning “novel one”<br />
in Korean. Trans<strong>for</strong>mation efficiency—the percentage of successful transgenic—was about 2%<br />
within progeny. The rate was lower, below 0.5%, if one success out of 204 transferred embryos<br />
was considered. Since 1999, a transgenic pig herd has been propagated. The gene transfer rate of<br />
the transgene reached 70% at F2 generation, as seen in Table 2.<br />
Table 2. Transfer Rate of the Transgene in Generations F1 through F3<br />
of a Transgenic Pig Herd<br />
Founder F1 F2 F3<br />
Number of transgenic individuals 1 82 30 34<br />
Gene transfer rate (%) 2.13 17.98 70.18 56.67<br />
The transgene now seems to have stabilized and is being inherited stably by the next generation.<br />
The sex ratio of progeny is about one to one, which suggests that the expression of the<br />
transgene does not inhibit survival of specific sexes during development. The milk from the<br />
transgenic female was examined. In this case study, one sow was milked after delivery <strong>for</strong> 50<br />
days during the lactation period, and about 880 units of human EPO were found in one milliliter<br />
of pig’s milk, about 8.8 grams per liter. The molecular weight <strong>for</strong> the EPO was about 34 kDa,<br />
similar to that of natural human EPO. The usual molecular weight of commonly used recombinant<br />
human EPO is about 50 kDa, which is a larger than natural EPO. After removal of glycosylation,<br />
this EPO showed the same molecular weight as commercial EPO that is identical to